BioCryst Pharmaceuticals(BCRX) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update — Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to$430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of$443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating pr ...